Payment overview · 2025
General Payments
$311.78
14 reported records · 12 companies
Healthcare provider profile · identity verified
Amandeep Pal, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · LOCKPORT, NY · NPI 1467694703
Verified facts
What the public records show
CMS Open Payments records show Amandeep Pal, MD received $311.78 in general payments during 2025 across 14 reported records.
Insulet Corporation accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 406 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1049 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $56.85 | 18.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.81 | 11.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.02 | 10.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.26 | 9.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.32 | 8.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.99 | 7.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.67 | 6.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.27 | 6.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.09 | 6.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.86 | 5.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.70 | 5.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.94 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $311.78 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $56.85 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.81 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.02 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1049 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 128 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 289 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
88 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
156 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
81 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
289 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
406 | 72 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
128 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
195 | 48 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
78 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1049 | 167 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 3074 | 705 |
| Amlodipine Besylate | Amlodipine Besylate | 2353 | 522 |
| Levothyroxine Sodium | Levothyroxine Sodium | 2164 | 391 |
| Metoprolol Succinate | Metoprolol Succinate | 1966 | 420 |
| Lisinopril | Lisinopril | 1790 | 398 |
| Gabapentin | Gabapentin | 1761 | 234 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1662 | 256 |
| Omeprazole | Omeprazole | 1285 | 224 |
| Eliquis | Apixaban | 1049 | 167 |
| Metoprolol Tartrate | Metoprolol Tartrate | 970 | 148 |
| Metformin Hcl | Metformin Hcl | 964 | 172 |
| Furosemide | Furosemide | 941 | 169 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 933 | 229 |
| Losartan Potassium | Losartan Potassium | 894 | 249 |
| Potassium Chloride | Potassium Chloride | 850 | 178 |
| Sertraline Hcl | Sertraline Hcl | 822 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 746 | 126 |
| Duloxetine Hcl | Duloxetine Hcl | 608 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 586 | 180 |
| Trazodone Hcl | Trazodone Hcl | 548 | 78 |
| Famotidine | Famotidine | 495 | 124 |
| Bumetanide | Bumetanide | 490 | 67 |
| Ozempic | Semaglutide | 479 | 118 |
| Clopidogrel | Clopidogrel Bisulfate | 478 | 94 |
| Simvastatin | Simvastatin | 452 | 100 |
| Hydralazine Hcl | Hydralazine Hcl | 445 | 108 |
| Levetiracetam | Levetiracetam | 443 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 428 | 62 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 428 | 133 |
| Baclofen | Baclofen | 423 | 38 |
| Metformin Hcl Er | Metformin Hcl | 415 | 99 |
| Jardiance | Empagliflozin | 406 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 402 | 140 |
| Carvedilol | Carvedilol | 391 | 47 |
| Atenolol | Atenolol | 373 | 79 |
| Lovastatin | Lovastatin | 373 | 60 |
| Allopurinol | Allopurinol | 368 | 65 |
| Glipizide | Glipizide | 362 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 349 | 72 |
| Donepezil Hcl | Donepezil Hcl | 333 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 317 | 21 |
| Ibuprofen | Ibuprofen | 298 | 75 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 289 | 58 |
| Memantine Hcl | Memantine Hcl | 284 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 252 | 72 |
| Prednisone | Prednisone | 248 | 47 |
| Ezetimibe | Ezetimibe | 247 | 57 |
| Alprazolam | Alprazolam | 246 | 65 |
| Bupropion Xl | Bupropion Hcl | 243 | 30 |
| Fenofibrate | Fenofibrate | 220 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 218 | 76 |
| Azithromycin | Azithromycin | 217 | 184 |
| Propranolol Hcl | Propranolol Hcl | 209 | 29 |
| Lamotrigine | Lamotrigine | 201 | 14 |
| Mirtazapine | Mirtazapine | 201 | 24 |
| Spironolactone | Spironolactone | 199 | 50 |
| Buspirone Hcl | Buspirone Hcl | 197 | 24 |
| Trulicity | Dulaglutide | 195 | 48 |
| Montelukast Sodium | Montelukast Sodium | 192 | 51 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 191 | 65 |
| Enalapril Maleate | Enalapril Maleate | 188 | 39 |
| Tramadol Hcl | Tramadol Hcl | 177 | 57 |
| Citalopram Hbr | Citalopram Hydrobromide | 173 | 39 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 172 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 169 | 36 |
| Nystatin | Nystatin | 169 | 57 |
| Xarelto | Rivaroxaban | 166 | 30 |
| Sucralfate | Sucralfate | 161 | 23 |
| Clonidine Hcl | Clonidine Hcl | 157 | 54 |
| Brilinta | Ticagrelor | 156 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 155 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 154 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 152 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 151 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 147 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 141 | 47 |
| Methylprednisolone | Methylprednisolone | 137 | 124 |
| Glipizide Er | Glipizide | 136 | 36 |
| Myrbetriq | Mirabegron | 135 | 15 |
| Torsemide | Torsemide | 134 | 21 |
| Mounjaro | Tirzepatide | 128 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 127 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 125 | 17 |
| Irbesartan | Irbesartan | 123 | 35 |
| Folic Acid | Folic Acid | 120 | suppressed |
| Meloxicam | Meloxicam | 118 | 26 |
| Finasteride | Finasteride | 117 | 27 |
| Digoxin | Digoxin | 116 | 16 |
| Warfarin Sodium | Warfarin Sodium | 115 | 26 |
| Celecoxib | Celecoxib | 112 | 36 |
| Primidone | Primidone | 111 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 107 | 19 |
| Alendronate Sodium | Alendronate Sodium | 106 | 33 |
| Clonazepam | Clonazepam | 106 | 31 |
| Divalproex Sodium | Divalproex Sodium | 102 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 101 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 27 |
| Pregabalin | Pregabalin | 101 | 26 |
| Risperidone | Risperidone | 99 | suppressed |
| Nifedipine Er | Nifedipine | 95 | 19 |
| Hydrocortisone | Hydrocortisone | 89 | 17 |
| Synthroid | Levothyroxine Sodium | 88 | 25 |
| Invokana | Canagliflozin | 86 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 15 |
| Farxiga | Dapagliflozin Propanediol | 81 | 26 |
| Meclizine Hcl | Meclizine Hcl | 81 | 35 |
| Propranolol Hcl Er | Propranolol Hcl | 81 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 81 | 68 |
| Vascepa | Icosapent Ethyl | 81 | 12 |
| Entresto | Sacubitril/Valsartan | 78 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 77 | 11 |
| Chlorthalidone | Chlorthalidone | 77 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 15 |
| Verapamil Er | Verapamil Hcl | 75 | suppressed |
| Latanoprost | Latanoprost | 74 | 19 |
| Colchicine | Colchicine | 73 | 18 |
| Glimepiride | Glimepiride | 68 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 66 | suppressed |
| Gemtesa | Vibegron | 65 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 63 | 21 |
| Lorazepam | Lorazepam | 63 | 16 |
| Midodrine Hcl | Midodrine Hcl | 62 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 60 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 21 |
| Methimazole | Methimazole | 57 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 27 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 53 | 13 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 53 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 50 | 13 |
| Rexulti | Brexpiprazole | 50 | suppressed |
| Diazepam | Diazepam | 49 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 27 |
| Gemfibrozil | Gemfibrozil | 49 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 48 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 17 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 46 | suppressed |
| Ramipril | Ramipril | 46 | suppressed |
| Olanzapine | Olanzapine | 45 | suppressed |
| Valsartan | Valsartan | 45 | 13 |
| Labetalol Hcl | Labetalol Hcl | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 35 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 42 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | 13 |
| Lactulose | Lactulose | 42 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 41 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 41 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Nyamyc | Nystatin | 39 | 18 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 14 |
| Topiramate | Topiramate | 38 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 29 |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 34 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 34 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 33 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | 11 |
| Naproxen | Naproxen | 33 | 12 |
| Rybelsus | Semaglutide | 33 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 33 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Repaglinide | Repaglinide | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 31 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 31 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | 11 |
| Cyclosporine | Cyclosporine | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 26 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Repatha Syringe | Evolocumab | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Nabumetone | Nabumetone | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | 15 |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | 16 |
| Amoxicillin | Amoxicillin | 22 | 12 |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nystop | Nystatin | 21 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Ramelteon | Ramelteon | 20 | suppressed |
| Acetazolamide | Acetazolamide | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 15 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Benzonatate | Benzonatate | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Galantamine Er | Galantamine Hbr | 18 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Zembrace Symtouch | Sumatriptan Succinate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | 11 |
| Trospium Chloride Er | Trospium Chloride | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $311.78 · 14 records | Insulet Corporation | AIRSUPRA, Auvelity, CAPLYTA, Cologuard Collection Kit, ELIQUIS, LEQVIO, MOUNJARO, NURTEC ODT, Omnipod, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error